MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-10-2022
Genmab A/S EBITDA per Share 2011-2026 | GMAB
Annual EBITDA per Share Genmab A/S
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 10.4 | 4.41 | 2.4 | 2.32 | 1.83 | 1.3 | 0.493 | 0.159 | -0.221 | - |
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.4 | -0.221 | 2.57 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
0.29 | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
3.32 | $ 46.2 | 4.01 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
-2.5 | $ 2.49 | 1.22 % | $ 69.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-0.22 | $ 6.85 | 1.93 % | $ 196 M | USA |
 |
Galectin Therapeutics
GALT
|
-0.31 | $ 2.28 | 2.24 % | $ 146 M | USA |
 |
Galapagos NV
GLPG
|
-2.53 | $ 28.82 | 1.51 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
0.87 | $ 8.4 | 1.51 % | $ 6.83 B |  Spain |
 |
Genprex
GNPX
|
-264 | $ 0.89 | 0.28 % | $ 830 K | USA |
 |
BioNTech SE
BNTX
|
62.6 | $ 94.21 | -1.35 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
-1.49 | $ 2.37 | 20.05 % | $ 152 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
-1.28 | $ 76.34 | 1.45 % | $ 12.2 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-0.6 | $ 1.49 | 3.83 % | $ 235 M | France |
 |
INmune Bio
INMB
|
-1.91 | $ 1.51 | -1.95 % | $ 37.4 M | USA |
 |
Kamada Ltd.
KMDA
|
-0.02 | $ 8.31 | 1.22 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
-4.04 | $ 85.92 | 3.88 % | $ 7.26 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-1.35 | $ 12.98 | -3.53 % | $ 1.72 B |  Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
1.4 | $ 23.02 | 2.98 % | $ 3.81 B | USA |
 |
Liquidia Corporation
LQDA
|
-0.58 | $ 41.73 | 3.97 % | $ 3.59 B | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.56 | 1.71 % | $ 5.86 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
0.04 | $ 106.77 | 0.9 % | $ 5.36 B | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
MannKind Corporation
MNKD
|
0.17 | $ 3.88 | 35.49 % | $ 1.19 B | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
-0.04 | $ 0.27 | -3.84 % | $ 660 M | Britain |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 23.63 | 0.9 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-1.49 | $ 39.36 | 13.2 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | USA |